Patent Application
20220193067
The present application claims priority to and benefit of the Chinese Patent Application No. 201910315417.X filed to China National Intellectual Property Administration on Apr. 19, 2019, the disclosure of which is incorporated herein by reference in its entirety.
The present invention relates to the field of medicines, and particularly relates to a quinoline compound or a pharmaceutically acceptable salt thereof for use in treating Ewing's sarcoma and a quinoline compound or a pharmaceutically acceptable salt thereof for combined treatment of Ewing's sarcoma.
Currently, Ewing's sarcoma is recognized as an independent bone tumor, and it is defined as a small round cell tumor of bone or soft tissue originating in neuroectoderm. Ewing's sarcoma accounts for 6%-8% of all primary bone tumors and 10%-14.2% of malignant bone tumors, and is second only to osteosarcoma and chondrosarcoma. It is the most common malignant primary bone tumor in children and adolescents, and is slightly more likely to be found in males than females.
The most common early symptoms of Ewing's sarcoma are pain and swelling, with more than 60% of patients presenting intermittent pain in the early stages and the pain sites spreading with tumor spread. Local lumps appear along with the aggravation of pain, and the patient experiences obvious pain when the lumps are pressed. Besides, symptoms of nerve function injury in nerve root, spinal cord, etc., appear. Some patients have fever at 38-40° C., and serum high density lipoprotein, cholesterol and red blood cell sedimentation rate increase significantly, accompanied by increased white blood cell count and anemia. Lesions can produce large soft tissue lumps. Because Ewing's sarcoma features high malignancy degree and rapid metastasis, the effect is not ideal when it is treated with only surgery, radiotherapy or single-drug chemotherapy, and the 5-year survival rate is no more than 10%.
At present, the more effective treatment method for Ewing's sarcoma is a combination therapy, i.e. a combination therapy of radiotherapy with chemotherapy and surgery (or without surgery), wherein for chemotherapy, multi-drug combination chemotherapy is the most common. Although research shows that the 5-year survival rate of Ewing's sarcoma can be remarkably improved by multi-drug combination chemotherapy and the like, the chemotherapy for Ewing's sarcoma generally lasts for 2 years because it mostly metastasizes within 2 years, and long-term chemotherapy results in toxic and side effects, such as complications of hematopoietic system, respiratory system, cardiovascular system, nervous system and urinary system. Therefore, there is an urgent need to develop new therapeutic regimens for Ewing's sarcoma.
In a first aspect, the present invention provides use of a compound of formula I or a pharmaceutically acceptable salt thereof in preparing a drug for treating Ewing's sarcoma.
The chemical name of the compound of formula I is 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin -7-yl]oxy]methyl]cyclopropylamine, which has the following structural formula:
In some embodiments, the Ewing's sarcoma is endoskeletal Ewing's sarcoma, extraskeletal Ewing's sarcoma or periosteal Ewing's sarcoma.
In some embodiments, the Ewing's sarcoma is osteolytic Ewing's sarcoma, sclerosing Ewing's sarcoma or hybrid Ewing's sarcoma.
In some embodiments, the Ewing's sarcoma is advanced Ewing's sarcoma. In some embodiments, advanced Ewing's sarcoma refers to primary or locally recurrent Ewing's sarcoma that cannot be eradicated by surgery or other local treatment, or that the patient refuses to treat with surgery or other local treatment. In some embodiments, advanced Ewing's sarcoma refers to one that, in the case of distal metastasis, cannot be eradicated by surgery or other local treatment, or that the patient refuses to treat with surgery or other local treatment.
In some embodiments, the Ewing's sarcoma is one that is after failure of a prior treatment. Preferably, the Ewing's sarcoma is one that is after failure of treatment with radiotherapy and/or a chemotherapeutic drug. More preferably, the Ewing's sarcoma is one that is after failure of treatment with the chemotherapeutic agent selected from one or more of cyclophosphamide, ifosfamide, doxorubicin, pirarubicin, dactinomycin, bleomycin, vincristine, carmustine, etoposide, actinomycin D, methotrexate and cisplatin. Most preferably, the chemotherapeutic agent that the subject with Ewing's sarcoma has received is selected from one or more of cyclophosphamide, ifosfamide, doxorubicin, pirarubicin, vincristine and etoposide.
The compound of formula I described herein can be administered in its free base form, or in the form of a salt, a hydrate, or a prodrug that may convert in vivo into the free base form of the compound of formula I. For example, within the scope of the present invention, the pharmaceutically acceptable salt of the compound of formula I can be generated from various organic and inorganic acids according to methods commonly known in the art.
In some embodiments, the pharmaceutically acceptable salt of the compound of formula I includes, but is not limited to, salts formed by the compound of formula I and any of the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentane propionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, p-toluenesulfonic acid, 3-phenylpropionic acid, trimethylacetic acid, t-butylacetic acid, dodecyl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid and stearic acid. In the present invention, the pharmaceutically acceptable salt of the compound of formula I is preferably in the form of hydrochloride or maleate, more preferably dihydrochloride.
In some embodiments, the compound of formula I or the pharmaceutically acceptable salt thereof is administered in the form of a hydrochloride. In some embodiments, the compound of formula I or the pharmaceutically acceptable salt thereof is administered in the form of a monohydrochloride. In some embodiments, the compound of formula I or the pharmaceutically acceptable salt thereof is administered in the form of a dihydrochloride. In some embodiments, the compound of formula I or the pharmaceutically acceptable salt thereof is administered in the form of a crystalline hydrochloride. In some embodiments, the compound of formula I or the pharmaceutically acceptable salt thereof is administered in the form of a crystalline dihydrochloride. In some embodiments, the compound of formula I or the pharmaceutically acceptable salt thereof is administered in the form of a maleate.
In another aspect, the present invention provides a method for use in treating Ewing's sarcoma, which comprises administering to a patient in need thereof a therapeutically effective amount of the compound of formula I or the pharmaceutically acceptable salt thereof.
The compound of formula I or the pharmaceutically acceptable salt thereof can be administered via multiple routes of administration including, but not limited to, oral, parenteral, intraperitoneal, intravenous, intra-arterial, transdermal, sublingual, intramuscular, rectal, transbuccal, intranasal, inhalational, vaginal, intraocular, topical, subcutaneous, intra-adipose, intra-articular and intrathecal administrations. In a specific embodiment, the drug is administered orally.
The dosage regimen of the compound of formula I can be determined comprehensively depending on the activity and toxicity of the drug, tolerance of a patient, etc.
In some embodiments, the compound of formula I or the pharmaceutically acceptable salt thereof can be provided in the form of a formulation suitable for any one of oral, parenteral, intraperitoneal, intravenous, intra-arterial, transdermal, sublingual, intramuscular, rectal, transbuccal, intranasal, inhalational, vaginal, intraocular, topical, subcutaneous, intra-adipose, intra-articular and intrathecal administrations, preferably in the form of a formulation suitable for oral administration. In some embodiments, the compound of formula I or the pharmaceutically acceptable salt thereof can be provided preferably in the form of tablets, capsules, powders, granules, dripping pills, pastes or pulvis, more preferably tablets or capsules.
In some embodiments, the administered amount of the compound of formula I or the pharmaceutically acceptable salt thereof can be determined according to the severity of a disease, the response of the disease, any treatment-related toxicity, and the age and health of a patient. In some embodiments, the compound of formula I or the pharmaceutically acceptable salt thereof is administered at a daily dose of 3 mg to 30 mg, preferably 5 mg to 20 mg, more preferably 8 mg to 16 mg, further preferably 8 mg to 14 mg, and most preferably 8 mg, 10 mg, or 12 mg.
Preferably, the compound of formula I or the pharmaceutically acceptable salt thereof is administered in an intermittent regimen. The intermittent regimen includes treatment periods and interruption periods. In the treatment period, the compound of formula I or the pharmaceutically acceptable salt thereof can be administered once or multiple times daily. For example, the compound of formula I or the pharmaceutically acceptable salt thereof is administered daily in the treatment period, and then the treatment is interrupted during the interruption period, followed by the treatment period and then the interruption period, over and over again. The ratio of the treatment period to the interruption period in days is 2:0.5-2:5, preferably 2:0.5-2:3, more preferably 2:0.5-2:2, and even more preferably 2:0.5-2:1.
As a still further preferred intermittent regimen, the intermittent regimen may be selected from one of the following cycles: consecutively 2-week treatment and then 2-week interruption, consecutively 2-week treatment and then 1-week interruption, and consecutively 5-day treatment and then 2-day interruption, wherein the cycle can be repeated multiple times.
In yet another aspect, the present invention provides a pharmaceutical composition for use in treating Ewing's sarcoma, which comprises the compound of formula I or the pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
The pharmaceutical composition includes, but is not limited to, a preparation suitable for oral, parenteral, intraperitoneal, intravenous, intra-arterial, transdermal, sublingual, intramuscular, rectal, transbuccal, intranasal, inhalational, vaginal, intraocular, topical, subcutaneous, intra-adipose, intra-articular and intrathecal administrations, preferably a preparation suitable for oral administration, including tablets, capsules, powders, granules, dripping pills, pastes and pulvis, and more preferably tablets or capsules. The tablet may be a common tablet, dispersible tablet, effervescent tablet, sustained-release tablet, controlled-release tablet or enteric coated tablet. The capsule may be a common capsule, sustained-release capsule, controlled-release capsule or enteric coated capsule. The oral preparation may be prepared by a conventional method using a pharmaceutically acceptable carrier well known in the art. The pharmaceutically acceptable carrier includes fillers, absorbents, wetting agents, binders, disintegrants, lubricants, and the like. The fillers include starch, lactose, mannitol, microcrystalline cellulose, and the like. The absorbents include calcium sulfate, calcium hydrogen phosphate, calcium carbonate, and the like. The wetting agents include water, ethanol, and the like. The binders include hydroxypropyl methylcellulose, polyvidone, microcrystalline cellulose, and the like. The disintegrants include croscarmellose sodium, crospovidone, surfactants, low-substituted hydroxypropyl cellulose, and the like. The lubricants include magnesium stearate, talcum powder, polyethylene glycol, sodium dodecyl sulfate, colloidal silicon dioxide, talcum powder, and the like. The pharmaceutically acceptable excipient further includes coloring agents, sweeteners and the like.
In one embodiment, the pharmaceutical composition is a solid preparation suitable for oral administration. The composition, for example, may be in the form of a tablet or capsule. In one specific embodiment, the pharmaceutical composition is a capsule. In one specific embodiment of the present invention, the pharmaceutically acceptable carrier of the oral solid preparation comprises mannitol, microcrystalline cellulose, hydroxypropylcellulose, and magnesium stearate.
In another aspect, the present invention provides use of a compound of formula I or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent in preparing a combination for treating Ewing's sarcoma.
In some embodiments, the Ewing's sarcoma includes, but is not limited to, endoskeletal Ewing's sarcoma, extraskeletal Ewing's sarcoma or periosteal Ewing's sarcoma.
In some embodiments, the Ewing's sarcoma includes, but is not limited to, osteolytic Ewing's sarcoma, sclerosing Ewing's sarcoma or hybrid Ewing's sarcoma.
In some embodiments, the Ewing's sarcoma is advanced Ewing's sarcoma. In some embodiments, advanced Ewing's sarcoma refers to primary or locally recurrent Ewing's sarcoma that cannot be eradicated by surgery or other local treatment, or that the patient refuses to treat with surgery or other local treatment. In some embodiments, advanced Ewing's sarcoma refers to one that, in the case of distal metastasis, cannot be eradicated by surgery or other local treatment, or that the patient refuses to treat with surgery or other local treatment.
In some embodiments, the Ewing's sarcoma includes, but is not limited to, one that is after failure of a prior treatment. Preferably, the Ewing's sarcoma is one that is after failure of treatment with radiotherapy and/or a chemotherapeutic drug. More preferably, the chemotherapeutic agent that a subject with Ewing's sarcoma has received is selected from one or more of cyclophosphamide, ifosfamide, doxorubicin, pirarubicin, dactinomycin, bleomycin, vincristine, carmustine, etoposide, actinomycin D, methotrexate and cisplatin. Most preferably, the chemotherapeutic agent that the subject with Ewing's sarcoma has received is selected from one or more of cyclophosphamide, ifosfamide, doxorubicin, pirarubicin, vincristine and etoposide.
In some embodiments, the second therapeutic agent is a chemotherapeutic drug, including, but not limited to, one or more of an alkylating agent, a podophyllum, a camptothecin analog, a taxane, an antimetabolite and an anti-tumor antibiotic. Examples that may be listed include, but are not limited to, one or more of a platinum-based drug (e.g., oxaliplatin, cisplatin, carboplatin, nedaplatin, and dicycloplatin), a fluoropyrimidine derivative (e.g., gemcitabine, capecitabine, fluorouracil, difuradin, doxifluridine, tegafur, carmofur, and trifluridine), a taxane (e.g., paclitaxel, albumin-bound paclitaxel, and docetaxel), a camptothecin analog (e.g., camptothecin, hydroxycamptothecin, irinotecan, and topotecan), a vinca alkaloid (vinorelbine, vinblastine, vincristine, vindesine, and vinflunine), pemetrexed, carmustine, etoposide, teniposide, mitomycin, ifosfamide, cyclophosphamide, azacitidine, doxorubicin, pirarubicin, amrubicin, methotrexate, bendamustine, epirubicin, actinomycin D, dactinomycin, bleomycin, temozolomide, LCL-161, KML-001, sapacitabine, plinabulin, treosulfan, tipiracil hydrochloride, 153Sm-EDTMP, tegafur-gimeracil-oteracil potassium, and encequidar. In some embodiments, the chemotherapeutic drug is selected from one or more of vincristine, cyclophosphamide, ifosfamide, doxorubicin, dactinomycin, bleomycin, carmustine, etoposide, actinomycin D, methotrexate, and cisplatin.
As required, the second therapeutic agent may be further used in combination with an ancillary drug for chemotherapy. The ancillary drug for chemotherapy includes but is not limited to calcium folinate (CF), leucovorin, mesna, bisphosphonate, amifostine, and hematopoietic cell colony stimulating factors (CSFs). In some embodiments, the ancillary drug for chemotherapy is CF, mesna, and leucovorin.
In some embodiments, the second therapeutic agent is a combination of camptothecin analogs and vinca alkaloids. In some embodiments, the second therapeutic agent is a combination of one of the camptothecin analogs and one of the vinca alkaloids. In some embodiments, the camptothecin analogs are selected from one or more of camptothecin, hydroxycamptothecin, irinotecan, and topotecan; the vinca alkaloids are selected from one or more of vinorelbine, vinblastine, vincristine, vindesine, and vinflunine.
In some embodiments, the second therapeutic agent is a combination of vinca alkaloids and one selected from the group consisting of camptothecin, hydroxycamptothecin, irinotecan, and topotecan. In some embodiments, the second therapeutic agent is a combination of camptothecin analogs and one selected from the group consisting of vinorelbine, vinblastine, vincristine, vindesine, and vinflunine. In some specific embodiments, the second therapeutic agent is a combination of irinotecan and vindesine.
In some embodiments, the second therapeutic agent is a VAC-1 regimen, specifically vincristine, cyclophosphamide, and actinomycin D.
In some embodiments, the second therapeutic agent is a VAC-2 regimen, specifically vincristine, cyclophosphamide, and doxorubicin.
In some embodiments, the second therapeutic agent is a T9 regimen, specifically doxorubicin, methotrexate, cyclophosphamide, actinomycin D, bleomycin, and vincristine.
In some embodiments, the second therapeutic agent is an IE regimen, specifically ifosfamide and etoposide.
In some embodiments, the second therapeutic agent is an AC regimen, specifically doxorubicin and cyclophosphamide.
In some embodiments, the second therapeutic agent is a small molecule targeted anti-tumor drug, including but not limited to protein kinase inhibitors, wherein the protein kinase inhibitors include, but are not limited to, tyrosine kinase inhibitors, serine and/or threonine kinase inhibitors, and poly ADP-ribose polymerase (PARP) inhibitors; targets of the inhibitors include, but are not limited to, epidermal growth factor receptor (EGFR), anaplastic lymphoma (ALK), MET gene, ROS1 gene, HER2 gene, RET gene, BRAF gene, PI3K signaling pathway, discoidin death receptor 2 (DDR2) gene, fibroblast growth factor receptor 1 (FGFR1), neurotrophic tyrosine kinase type 1 receptor (NTRK1) gene, and KRAS gene. Targets of the small molecule targeted anti-tumor drug further include COX-2 (cyclooxygenase-2), APE1 (apurinic apyrimidinic endonuclease), VEGFR-2 (vascular endothelial growth factor receptor-2), CXCR-4 (chemokine receptor-4), MMP (matrix metalloproteinase), IGF-1R (insulin-like growth factor receptor), Ezrin, PEDF (pigment epithelium derived factor), AS, ES, OPG (osteoprotegerin), Src, IFN, ALCAM (activated leukocyte cell adhesion molecule), HSP, JIP1, GSK-3β (glycogen synthesis kinase 3β), CyclinD1 (cell cycle regulatory protein), CDK4 (cyclin-dependent kinase), TIMP1 (tissue inhibitor of metalloproteinase), THBS3, PTHR1 (parathyroid hormone-related protein receptor 1), TEM7 (tumor endothelial marker 7), COPS3, and cathepsin K. Examples of small molecule targeted anti-tumor drug include, but are not limited to, one or more of erlotinib, afatinib, crizotinib, ceritinib, vemurafenib, dabrafenib, cabozantinib, gefitinib, dacomitinib, osimertinib, alectinib, brigatinib, lorlatinib, trametinib, larotrectinib, icotinib, lapatinib, vandetanib, selumetinib, sorafenib, olmutinib, savolitinib, fruquintinib, entrectinib, dasatinib, ensartinib, lenvatinib, itacitinib, pyrotinib, binimetinib, erdafitinib, axitinib, neratinib, cobimetinib, acalabrutinib, famitinib, masitinib, ibrutinib, rociletinib, nintedanib, lenalidomide, everolimus, LOXO-292, vorolanib, bemcentinib, capmatinib, entrectinib, TAK-931, ALT-803, palbociclib, famitinib L-malate, LTT-462, BLU-667, ningetinib, tipifarnib, poziotinib, DS-1205c, capivasertib, SH-1028, dimethyldiguanide, seliciclib, OSE-2101, APL-101, berzosertib, idelalisib, lerociclib, ceralasertib, PLB-1003, tomivosertib, AST-2818, SKLB-1028, D-0316, LY-3023414, allitinib, MRTX-849, AP-32788, AZD-4205, lifirafenib, vactosertib, mivebresib, napabucasin, sitravatinib, TAS-114, molibresib, CC-223, rivoceranib, CK-101, LXH-254, simotinib, GSK-3368715, TAS-0728, masitinib, tepotinib, HS-10296, AZD-4547, merestinib, olaptesed pegol, galunisertib, ASN-003, gedatolisib, defactinib, lazertinib, CKI-27, S-49076, BPI-9016M, RF-A-089, RMC-4630, AZD-3759, antroquinonol, SAF-189s, AT-101, TTI-101, naputinib, LNP-3794, HH-SCC-244, ASK-120067, CT-707, epitinib succinate, tesevatinib, SPH-1188-11, BPI-15000, copanlisib, niraparib, olaparib, veliparib, talazoparib tosylate, DV-281, siremadlin, telaglenastat, MP-0250, GLG-801, ABTL-0812, bortezomib, panobinostat, tucidinostat, vorinostat, resminostat, epacadostat, tazemetostat, entinostat, mocetinostat, and quisinostat. In some embodiments, the small molecule targeted anti-tumor drug is one or more of sorafenib, everolimus, erlotinib, afatinib, crizotinib, ceritinib, vemurafenib, dabrafenib, cabozantinib, gefitinib, dacomitinib, osimertinib, alectinib, brigatinib, lorlatinib, trametinib, larotrectinib, icotinib, lapatinib, vandetanib, selumetinib, olmutinib, savolitinib, fruquintinib, entrectinib, dasatinib, ensartinib, lenvatinib, itacitinib, pyrotinib, binimetinib, erdafitinib, axitinib, neratinib, cobimetinib, acalabrutinib, famitinib, masitinib, ibrutinib and nintedanib.
In some embodiments, the administered amount of the compound of formula I or the pharmaceutically acceptable salt thereof in the combination can be determined according to the severity of a disease, the response of the disease, any treatment-related toxicity, and the age and health of a patient. In some embodiments, the daily dose of the compound of formula I or the pharmaceutically acceptable salt thereof is 3 mg to 30 mg. In some embodiments, the daily dose of the compound of formula I or the pharmaceutically acceptable salt thereof is 5 mg to 20 mg. In some embodiments, the daily dose of the compound of formula I or the pharmaceutically acceptable salt thereof is 8 mg to 16 mg. In some embodiments, the daily dose of the compound of formula I or the pharmaceutically acceptable salt thereof is 8 mg to 14 mg. In a specific embodiment, the daily dose of the compound of formula I or the pharmaceutically acceptable salt thereof is 8 mg. In a specific embodiment, the daily dose of the compound of formula I or the pharmaceutically acceptable salt thereof is 10 mg. In a specific embodiment, the daily dose of the compound of formula I or the pharmaceutically acceptable salt thereof is 12 mg.
The compound of formula I or the pharmaceutically acceptable salt thereof can be administered once or multiple times daily. In some embodiments, the compound of formula I or the pharmaceutically acceptable salt thereof is administered once daily.
The dosage regimen of the compound of formula I can be determined comprehensively depending on the activity and toxicity of the drug, tolerance of a patient, etc.
Preferably, the compound of formula I or the pharmaceutically acceptable salt thereof is administered in an intermittent regimen. The intermittent regimen includes treatment periods and interruption periods. In the treatment period, the compound of formula I or the pharmaceutically acceptable salt thereof can be administered once or multiple times daily. For example, the compound of formula I or the pharmaceutically acceptable salt thereof is administered daily in the treatment period, and then the treatment is interrupted during the interruption period, followed by the treatment period and then the interruption period, over and over again. The ratio of the treatment period to the interruption period in days is 2:0.5-2:5, preferably 2:0.5-2:3, more preferably 2:0.5-2:2, and even more preferably 2:0.5-2:1.
In some embodiments, the compound of formula I or the pharmaceutically acceptable salt thereof is administered according to one of the following intermittent regimens: consecutively 2-week treatment and then 2-week interruption, consecutively 2-week treatment and then 1-week interruption, and consecutively 5-day treatment and then 2-day interruption, wherein the cycle can be repeated multiple times.
In some embodiments, the compound of formula I or the pharmaceutically acceptable salt thereof and the second therapeutic agent are administered simultaneously, sequentially, or nonsimultaneously. In some embodiments, the compound of formula I or the pharmaceutically acceptable salt thereof and the second therapeutic agent are administered after being prepared into a pharmaceutical composition.
In some embodiments, the combination for use in treating Ewing's sarcoma includes, but is not limited to, formulations suitable for any of oral, parenteral, intraperitoneal, intravenous, intra-arterial, transdermal, sublingual, intramuscular, rectal, transbuccal, intranasal, inhalational, vaginal, intraocular, topical, subcutaneous, intra-adipose, intra-articular and intrathecal administrations.
The compound of formula I or the pharmaceutically acceptable salt thereof is preferably preparations suitable for oral administration, including tablets, capsules, powders, granules, dripping pills, pastes, pulvis and the like, and preferably tablets and capsules. The tablet may be a common tablet, a dispersible tablet, an effervescent tablet, a sustained-release tablet, a controlled-release tablet or an enteric coated tablet; the capsule may be a common capsule, a sustained-release capsule, a controlled-release capsule or an enteric coated capsule. The oral preparation may be prepared by a conventional method using a pharmaceutically acceptable carrier well known in the art. The pharmaceutically acceptable carrier includes fillers, absorbents, wetting agents, binders, disintegrants, lubricants, and the like. The fillers include starch, lactose, mannitol, microcrystalline cellulose, and the like. The absorbents include calcium sulfate, calcium hydrogen phosphate, calcium carbonate, and the like. The wetting agents include water, ethanol, and the like. The binders include hydroxypropyl methylcellulose, polyvidone, microcrystalline cellulose, and the like. The disintegrants include croscarmellose sodium, crospovidone, surfactants, low-substituted hydroxypropyl cellulose, and the like. The lubricants include magnesium stearate, talcum powder, polyethylene glycol, sodium dodecyl sulfate, colloidal silicon dioxide, talcum powder, and the like. The pharmaceutically acceptable excipient further includes coloring agents, sweeteners and the like.
In certain specific embodiments, irinotecan is administered intravenously at a dosage of 10-40 mg/m2; and meanwhile the compound of formula I or the pharmaceutically acceptable salt thereof is orally administered once or multiple times daily at a dosage selected from but not limited to 3-30 mg, and the administration regimen is consecutively 2-week treatment and then 1-week interruption.
In certain specific embodiments, irinotecan is administered intravenously at a dosage of 10-40 mg/m2, vindesine is administered at a dosage of 1-4mg/m2; and meanwhile the compound of formula I or the pharmaceutically acceptable salt thereof is orally administered once or multiple times daily at a dosage selected from but not limited to 3-30 mg, and the administration regimen is consecutively 2-week treatment and then 1-week interruption.
In certain specific embodiments, irinotecan is administered at a dosage 10-40 mg/m2, vindesine is administered at a dosage of 1-4 mg/m2, and the compound of formula I or the pharmaceutically acceptable salt thereof is orally administered once or multiple times daily at a dosage of 8-12 mg, while the administration regimen is consecutively 2-week treatment and then 1-week interruption. In some specific embodiments, irinotecan is administered at a dosage of 10, 15, 20, 25, 30, 35 or 40 mg/m2 each time, vindesine is administered at a dosage of 1, 2, 3 or 4 mg/m2 each time, and the compound of formula I or the pharmaceutically acceptable salt thereof is orally administered daily at a dosage of 8-12 mg, while the administration regimen is consecutively 2-week treatment and then 1-week interruption.
In certain specific embodiments, every three weeks constitute a treatment cycle, wherein irinotecan is administered on days 1-5 and 8-10 of each cycle, vindesine is administered on days 1 and 8 of each cycle, and the compound of formula I or the pharmaceutically acceptable salt thereof is administered on days 1-14 of each cycle.
In a specific embodiment, every three weeks constitute a treatment cycle, wherein irinotecan is administered once daily on days 1-5 and 8-10 of each cycle at a dosage of 10, 15 or 20 mg/m2, vindesine is administered once daily on days 1 and 8 of each cycle at a dosage of 2, 3 or 4 mg/m2, and the compound of formula I or the pharmaceutically acceptable salt thereof is administered once daily on days 1-14 of each cycle at a dosage of 8-12 mg.
In certain specific embodiments, vincristine is administered intravenously once a week at a dosage of 1.5 mg/m2, cyclophosphamide is administered intravenously once a week at a dosage of 500 mg/m2, and the treatment with the two chemotherapeutic drugs lasts for 6 weeks; after 6 weeks, the two chemotherapeutic drugs are each administered intravenously once a week at the same dosage described above, and meanwhile the compound of formula I or the pharmaceutically acceptable salt thereof is orally administered once or multiple times daily at a dosage of 3-30 mg, while the administration regimen is consecutively 2-week treatment and then 1-week interruption and radical operation is also performed.
In certain specific embodiments, actinomycin D is administered intravenously at a dosage of 450 μg/m2 (once daily, 5 times in total); intravenous administration of doxorubicin at a dosage of 20 mg/m2 is started on days 15 and 29 (once daily, 3 times in total for each); intravenous administration of vincristine at a dosage of 1.5 mg/m2 is started on day 43 (once a week, 4 times in total), and cyclophosphamide is administered intravenously at a dosage of 1200 mg/m2 (once every 2 weeks, 2 times in total); the compound of formula I or the pharmaceutically acceptable salt thereof is orally administered once or multiple times daily at a dosage selected from but not limited to 3-30 mg, and the administration regimen is consecutively 2-week treatment and then 1-week interruption.
In certain specific embodiments, the compound of formula I or the pharmaceutically acceptable salt thereof is used in combination with a VAC-1 regimen. The method is as follows: vincristine is administered intravenously at a dosage of 2 mg on day 1; actinomycin D is infused intravenously at a dosage of 2 mg/m2 on day 1; cyclophosphamide is infused intravenously at a dosage of 1200 mg/m2 on day 1; the compound of formula I or the pharmaceutically acceptable salt thereof is orally administered once or multiple times daily at a dosage selected from but not limited to 3-30 mg, and the administration regimen is consecutively 2-week treatment and then 2-week interruption , with 28 days being a cycle.
In certain specific embodiments, the compound of formula I or the pharmaceutically acceptable salt thereof is used in combination with a VAC-2 regimen. The method is as follows: vincristine is administered intravenously at a dosage of 2 mg on day 1; doxorubicin is infused intravenously at a dosage of 75 mg/m2 on day 1; cyclophosphamide is infused intravenously at a dosage of 1200 mg/m2 on day 1; the compound of formula I or the pharmaceutically acceptable salt thereof is orally administered once or multiple times daily at a dosage selected from but not limited to 3-30 mg, and the administration regimen is consecutively 5-day treatment and then 2-day interruption, with 7 days being a cycle.
In certain specific embodiments, the compound of formula I or the pharmaceutically acceptable salt thereof is used in combination with a T9 regimen. The method is as follows: doxorubicin is infused intravenously at a dosage of 20 mg/m2 on days 1-3 and 42-44; methotrexate is infused intravenously at a dosage of 12 mg/m2 on days 1-3 and 42-44; cyclophosphamide is infused intravenously at a dosage of 1.2 g/m2 on days 1 and 42; actinomycin D is infused intravenously at a dosage of 0.5 mg/m2 on days 21-23; bleomycin is infused intravenously at a dosage of 10 mg/m2 on days 21-23; vincristine is infused intravenously at a dosage of 1.5 mg/m2 on days 1, 7, 14, 21 and 30; the compound of formula I or the pharmaceutically acceptable salt thereof is orally administered once or multiple times daily at a dosage selected from but not limited to 3-30 mg, and the administration regimen is consecutively 5-day treatment and then 2-day interruption.
In certain specific embodiments, the compound of formula I or the pharmaceutically acceptable salt thereof is used in combination with an IE regimen and an AC regimen sequentially. The method is as follows: ifosfamide is infused intravenously at a dosage of 1.6 g/m2 on days 1-5; etoposide is infused intravenously at a dosage of 100 mg/m2 on day 15; 21 days constitute one cycle, and after 3 cycles, doxorubicin is infused intravenously at a dosage of 35 mg/m2 on day 8; cyclophosphamide is orally administered at a dosage of 1.50 g/m2 on days 1-7; the compound of formula I or the pharmaceutically acceptable salt thereof is orally administered once or multiple times daily at a dosage selected from but not limited to 3-30 mg, and the administration regimen is consecutively 2-week treatment and then 1-week interruption.
In another aspect, the present invention provides a method for treating Ewing's sarcoma, which comprises administering to a patient in need thereof, simultaneously, at intervals or sequentially, a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a second therapeutic agent.
In yet another aspect, the present invention provides a combined pharmaceutical composition for use in treating Ewing's sarcoma, which comprises a compound of formula I or a pharmaceutically acceptable salt thereof, and a second therapeutic agent.
Compared with the prior art, the present invention has the following beneficial effects: the compound of formula I or the pharmaceutically acceptable salt thereof is used for treating Ewing's sarcoma, and has remarkable therapeutic effect; the compound of formula I or the pharmaceutically acceptable salt thereof is used in combination with the second therapeutic agent, and the compound of formula I or the pharmaceutically acceptable salt thereof can obviously enhance the killing effect of the drug, particularly the chemotherapeutic drug, on Ewing's sarcoma, and meanwhile reduce the dosage of the chemotherapeutic drug, thereby reducing the side effect. The present invention provides a new idea for treating Ewing's sarcoma, in particular for the second-line treatment of the Ewing's sarcoma which is after failure of a prior treatment with radiotherapy and chemotherapeutic drugs.
Unless otherwise stated, the following terms used in the specification and claims shall have the following meanings for the purposes of the present invention.
In the present application, in the case of anlotinib, the active ingredient always refer to the compound of formula I.
In the present application, unless otherwise stated, the dosages and ranges provided herein for the compound of formula I or the pharmaceutically acceptable salt thereof are based on the molecular weight of the free base of the compound of formula I.
“Patient” refers to a mammal, preferably a human. As used herein, “patient,” “subject,” or “entity” are used interchangeably.
As used herein, the term “combined pharmaceutical composition” refers to a combination of two or more active ingredients (administered as the respective active ingredients themselves, or as their respective derivatives like pharmaceutically acceptable salts or esters, prodrugs, or compositions) that are administered simultaneously or sequentially. As used herein, the terms “combined pharmaceutical composition”, “combination” and “pharmaceutical combination” are used interchangeably.
As used herein, “combined use” or “use in combination” means that two or more active substances may be administered to a subject simultaneously or sequentially in any order as a single formulation.
“Pharmaceutically acceptable” refers to that when a substance is used for preparing a pharmaceutical composition, the pharmaceutical composition is generally safe, non-toxic, and desirable biologically and otherwise, and inclusion of the substance is acceptable for pharmaceutical use in human.
The “pharmaceutically acceptable salt” includes, but is not limited to, acid addition salts of inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid, or acid addition salts of organic acids such as acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentane propionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, p-toluenesulfonic acid, 3-phenylpropionic acid, trimethylacetic acid, t-butylacetic acid, dodecyl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, and stearic acid.
The term “therapeutically effective amount” refers to an amount of a compound that, when administered to a human for use in treating a disease, is sufficient to effectively control the disease.
“Treat” or “treatment” or “treating” refers to any administration of a therapeutically effective amount of a compound, and includes:
(1) suppressing a disease in a human experiencing or exhibiting the pathology or symptomatology of the disease (i.e., preventing further pathological and/or symptomatological progression), or
(2) relieving the disease in a human experiencing or exhibiting the pathology or symptomatology of the disease (i.e., reversing the pathology and/or symptomatology).
As used herein, unless otherwise stated, the terms “comprise”, “comprises” and “comprising” or equivalents thereof are open-ended statements and mean that elements, components and steps that are not specified may be included in addition to those listed.
All patents, patent applications and other identified publications are expressly incorporated herein by reference for the purpose of description and disclosure. These publications are provided solely because they were disclosed prior to the filing date of the present application. All statements as to the dates of these documents or description as to the contents of these documents are based on the information available to the applicant and do not constitute any admission as to the correctness of the dates of these documents or the content of these documents. Moreover, in any country or region, any reference to these publications herein is not to be construed as an admission that the publications form part of the commonly recognized knowledge in the art.
The present invention will be further illustrated with reference to the following specific examples and experimental examples. These examples, however, are merely intended to illustrate the present invention rather than limit the scope of the present invention. Experimental procedures without specified experiment conditions in the following examples were performed in accordance with conventional conditions.
Example 1. 1-1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine dihydrochloride (dihydrochloride of the compound of formula I)
1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine was prepared by referring to Example 24 of WO2008112407, and then the title compound was prepared by referring to the preparation method of “Examples of salt formation” in the specification of WO2008112407.
Alternatively, the title compound was prepared by referring to the method disclosed in Chinese Patent Application No. CN102344438A.
Example 2. Preparation of Capsule of 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl] oxy]methyl]cyclopropylamine dihydrochloride (dihydrochloride of the compound of formula I)
The dihydrochloride of the compound of formula I was ground, sieved with an 80-mesh sieve, and well mixed with mannitol and hydroxypropyl cellulose. A predetermined amount of microcrystalline cellulose was added, and the resulting mixture was well mixed and sieved with a 0.8-mm sieve. Finally, a predetermined amount of magnesium stearate was added and the resulting mixture was well mixed to fill capsules.
Capsules with different amount of the dihydrochloride of the compound of formula I can be prepared as per the same proportions and formulation as described above.
Example 3. Efficacy Experiment
Test drug:
1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine dihydrochloride (dihydrochloride of the compound of formula I for short); vincristine; doxorubicin; cyclophosphamide.
1. Effect of dihydrochloride of the compound of formula I on growth of Ewing's sarcoma
Preparation method:
The dihydrochloride salt of the compound of formula I was dissolved in water to a concentration of 25 mg/mL and then further diluted with distilled water to a concentration of 250 μg/mL.
Preparation of experimental animals:
BALB/cA-nude mice, feeding environment: SPF grade. Nude mice were inoculated subcutaneously with human Ewing's sarcoma cells A673, and randomly grouped (d0) after tumors grew to 100-250 mm3.
Experimental procedures:
The dihydrochloride of the compound of formula I (a dosage of 6.25 mg/kg) was orally administered daily to the animals in a volume of 10 mL/kg for 14 consecutive days. The tumor volume was measured 2-3 times per week, the mice were weighed, and the data was recorded.
The equation for calculating tumor volume (V) is as follows: V=½×a×b2, where a and b represent length and width, respectively.
T/C (%)=(T-T0)/(C-C0)×100%, where T and C represent the tumor volumes of the administration group mice and the control group (i.e., solvent group) mice, respectively, at the end of the experiment; T0 and C0 represent the tumor volumes of administration group mice and the control group (i.e., solvent group) mice, respectively, at the time of grouping and administration (d0).
The equation for calculating relative tumor volume (RTV) after administration is as follows: RTV=TV/TV0 (TV represents tumor volume at each measurement after administration, and TV0 represents tumor volume at the time of grouping and administration (d0)).
Experimental results show that 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine dihydrochloride (dihydrochloride of the compound of formula I) can significantly inhibit the growth of Ewing's sarcoma.
2. Effect of the combination of the dihydrochloride of the compound of formula I and a second therapeutic agent on proliferation of Ewing's sarcoma cells
Preparation method:
The test drugs were dissolved in dimethyl sulfoxide to prepare a 100 mmol/L mother solution, which was stored at −20° C. for later use. When in use, the mother solution was prepared with a DMEM serum culture medium to reach a required concentration; vincristine, doxorubicin and cyclophosphamide were mixed (VAC-2 regimen), and the dihydrochloride diluent of the compound of formula I was mixed with vincristine, doxorubicin and cyclophosphamide.
Cell culturing:
Human Ewing's sarcoma cell line A673 was cultured in a DMEM complete culture medium containing 10% fetal bovine serum and 0.1 g/L streptomycin and penicillin (final concentration: 100 U.mL−1), and the mixture was incubated in an incubator at 37° C./5% CO2. When the cell confluence reached about 85%, the cells were mixed and digested using 0.02% EDTA and 0.25% trypsin, and then the cells were collected, centrifuged at 1000 r/min, and subcultured.
Experimental procedures:
The ICso value can be measured by a conventional method in the art (e.g., MTT method), or can be measured by the following method (MTT method):
Cells in logarithmic growth phase were inoculated in a 96-well culture plate (180 μL/well, 105 cells/well); after 2 h of incubation at 37° C./5% CO2, the cells were added with the dihydrochloride of the compound of formula I (solutions at gradient concentrations of 0, 0.005, 0.1, 0.05, 0.1, 0.5, 1.5, 4, 12 and 30 μg/mL), 2 μg/mL vincristine, 75 μg/mL doxorubicin and 500 μg/mL cyclophosphamide, and the resulting mixtures were incubated. Two duplicate wells were set for each concentration, 20 μL added for each well. Meanwhile, wells for normal saline solvent controls with corresponding concentrations and cell-free zeroing wells were set. The tumor cells were incubated at 37° C./5% CO2 for 24 h (i.e., 48 h in total); after the drug effect was finished, MTT working solution was added into each well, and after 4 h, the combination solution of three drugs was added for dissolving. The resulting mixtures were left to stand overnight at 37° C. The next day, OD values were measured at 570 nm and 630 nm wavelengths using a microplate reader (SPECTRA max 190) (calculated by subtracting OD values measured at 630 nm (the control wavelength) from all OD values measured at 570 nm), and the cell growth inhibition rate was calculated according to the following equation:
Inhibition rate=(OD value of control well−OD value of administration well)/OD value of control well×100%
Half maximal inhibitory concentration IC50 was calculated according to inhibition rates at all concentrations using GraphPad Prism 5 software.
Experimental results:
The in vitro pharmacodynamic effect of the combined therapy (dihydrochloride of the compound of formula I, vincristine, doxorubicin and cyclophosphamide) and the positive control (vincristine, doxorubicin and cyclophosphamide) on human Ewing's sarcoma A673 cells shows that the combination of the dihydrochloride of the compound of formula I with a second therapeutic agent has definite inhibition effect on the proliferation of the human Ewing's sarcoma A673 cells.
3. Effect of the combination of the dihydrochloride of the compound of formula I and a second therapeutic agent on apoptosis of Ewing's sarcoma cells
Detection of apoptosis using flow cytometry
Human Ewing's sarcoma A673 cells in logarithmic growth phase were added at 105 cells/well to a DMEM complete culture medium containing 2 μg/mL vincristine, 75 μg/mL doxorubicin and 500 μg/mL cyclophosphamide, and to a DMEM complete culture medium containing the dihydrochloride of the compound of formula I (at concentrations of 0, 0.005, 0.1, 0.05, 0.1, 0.5, 1.5, 4, 12 and 30 μg/mL), 2 μg/mL vincristine, 75 μg/mL doxorubicin and 500 μg/mL cyclophosphamide. The resulting mixtures were incubated for 24 h, and then the cells were collected, centrifuged at 1000 r/min for 3-5 min, and washed with PBS. Then the apoptosis of the cells was detected using an Annexin-V-FITC/PI apoptosis detection kit. The cells were resuspended in 100 μL of 1×Binding buffer solution, and 5 μL of Annexin-V-FITC and 2.5 μL of PI dye were added. The mixture was shaken and mixed well in the absence of light, reacted for 15 min at room temperature, added with 300 μL of 1×Binding buffer solution, mixed well, and then subjected to detection by a flow cytometer. The test was repeated 3 times.
Test results:
The results based on a classical Annexin-V-FITC/PI apoptosis detection method show that the dihydrochloride of the compound of formula I at different concentrations can remarkably enhance apoptosis of an Ewing's sarcoma cell line caused by the vincristine+doxorubicin+cyclophosphamide regimen (VAC-2 regimen).
Example 4. Clinical Trial
A clinical trial was carried out in Ewing's sarcoma patients with measurable lesions (according to RECIST 1.1) for the combination of the dihydrochloride capsule of the compound of formula I and a second therapeutic agent (VAC-2 regimen). Patients in the patient group comprised patients who had previously received chemotherapy and those who had not. The patients were orally administered with 12 mg of the dihydrochloride capsule of the compound of formula I once daily (2 weeks of treatment and 1 week of interruption constitute one treatment cycle), and meanwhile the patients were treated with the VAC-2 regimen: intravenous infusion of 2 mg of vincristine on day 1, intravenous infusion of 75 mg/m2 of doxorubicin on day 1, and intravenous infusion of 1200 mg/m2 of cyclophosphamide on day 1 (28 days constitute one cycle). The evaluation endpoints included: efficacy endpoints, e.g., progression-free survival (PFS), objective response rate (ORR), duration of response (DOR), stable disease (SD) rate, clinical benefit rate (CBR), overall survival (OS), etc.; safety endpoints, e.g., incidence and severity of adverse events; and quality of life. The clinical trial results are as follows:
The combination of the dihydrochloride of the compound of formula I and the VAC-2 regimen is effective for treatment of Ewing's sarcoma, and can prolong overall survival, etc.
Example 5
Patient, male, 29 years old, left pubic aspiration biopsy performed in November 2014, pathologically diagnosed as small round cell malignancy. Clinical diagnosis: metastasis to both lungs following left pubic Ewing's sarcoma postoperative chemotherapy.
From November 2014 to October 2018, the patient had received 9 cycles of treatment with vincristine (VCR), doxorubicin (ADM) and cyclophosphamide (CTX), and 10 cycles of treatment with ifosfamide (IFO) and etoposide (VP-16); grade III myelosuppression was observed a plurality of times during chemotherapy. In March 2015, the patient received “huge pelvic tumor resection +hemipelvectomy under exclusion of hip joint” under general anesthesia. Postoperative pathology: small cell malignancy (left hip), which was most probably Ewing's sarcoma according to immunophenotyping and molecular detection results. The patient then received 2 cycles of chemotherapy with “vincristine+doxorubicin+cyclophosphamide” from December 2018, and the CT scanning and other examinations in March 2019 showed disease progression in lungs, and the chemotherapy effect is not ideal. The patient then started the treatment with an anlotinib dihydrochloride capsule (the active ingredient is the compound of formula I), which was orally administered once daily at a dosage of 12 mg (2 weeks of treatment and 1 week of interruption constitute one treatment cycle).
One week prior to treatment with the anlotinib dihydrochloride capsule, CT scan showed that the sum of the diameters of measurable target lesions (nodules at left lower lung) was 16 mm. CT scanning was carried out periodically after administration, and the sum of the diameters of the target lesions was reduced to 10 mm after 10 weeks of treatment. The therapeutic effect featuring reduce of 37.5% was evaluated as partial response (PR). The sum of the diameters of the target lesions was reduced to 9 mm after 16 treatment cycles, the therapeutic effect was evaluated as PR, and no new lesions were observed. During treatment, the overall tolerability was good and the patient is still receiving the treatment.
Example 6
Patient, male, 28 years old. Aspiration biopsy was performed in 2016 and the pathological diagnosis result was peripheral primitive neuroectodermal tumor. Clinical diagnosis: metastasis to both lungs following sacral Ewing's sarcoma/primitive neuroectodermal tumor postoperative chemotherapy.
From May 2016 to July 2016, the patient received the following treatments successively: liposomal doxorubicin 40 mg d1+cyclophosphamide 1g d1; ifosfamide 4g d1-3+etoposide 100 mg d1-3; liposomal doxorubicin 40 mg d1+cyclophosphamide 1 g d1; ifosfamide 4 g d1-3+etoposide 100 mg d1-3. In August 2016, the patient received “posterior sacral tumor resection and fixation” under general anesthesia, and postoperative pathology indicated small round cell malignancy of sacrum, which tends to be Ewing's sarcoma/primitive neuroectodermal tumor. Five cycles of postoperative chemotherapy were carried out, including: epirubicin 110 mg d1+cyclophosphamide 1 g dl; ifosfamide 4 g d1-3 +etoposide 100 mg d1-3; epirubicin 110 mg d1+cyclophosphamide 1 g d1+vindesine 3 mg dl; ifosfamide 4 g d1-3+etoposide 100 mg d1-3; and epirubicin 110 mg d1+cyclophosphamide 1 g dl +vindesine 3 mg dl. After chemotherapy, grade II myelosuppression was observed, and the time of the last chemotherapy was February 2017. In August 2017, the patient was administered successively with irinotecan 40 mg d1-4+temozolomide 140 mg d1-5, and irinotecan 40 mg. From September 2017, the patient was administered successively with irinotecan 40 mg d1-4+temozolomide 140 mg d1-5, irinotecan 40 mg, irinotecan 40 mg d1-4+cyclophosphamide 500 mg d1-4, and irinotecan 40 mg d1-4+temozolomide 140 mg d1-5.
In January 2019, the patient started the treatment with an anlotinib dihydrochloride capsule, which was orally administered once daily at a dosage of 12 mg (2 weeks of treatment and 1 week of interruption constitute one treatment cycle).
Three days before administration of anlotinib dihydrochloride capsule, CT scan showed that the sum of diameters of measurable target lesions was 36 mm (36 mm at lower lobe of right lung). After each treatment cycle was completed, CT scan was performed immediately, and the results are shown in Table 1 below. The subject has received 20 cycles of drug administration at present, and the doctor, after assessment, advises that the drug administration shall be continued. The overall tolerance was good during the treatment.
Example 7
Patients with advanced Ewing's sarcoma who failed a prior treatment were divided into groups A and B. Group A had 23 patients aged 16 years or over, and they were provided with the following treatment: once-daily oral administration of anlotinib dihydrochloride capsule 12 mg d1-d14 (2 weeks of treatment and 1 week of interruption constitute one treatment cycle)+once-daily intravenous administration of irinotecan 15 mg/m2 d1-d5, d8-d10 (3 weeks constitute one treatment cycle)+vindesine 3 mg/m2 (administration on d1 and d8, 3 weeks constitute one treatment cycle). Group B had 12 patients younger than 16 years, and they were provided with the following treatment: once-daily oral administration of anlotinib dihydrochloride capsule (2 weeks of treatment and 1 week of interruption constitute one treatment cycle, and the dosages were determined as per body surface area (BSA) and are specifically as follows: BSA <1.0 m2, 8 mg, d1-d14; BSA 1.0 m2, 12 mg, d1-d14)+once-daily intravenous administration of irinotecan 20 mg/m2 d1-d5, d8-d10 (3 weeks constitute one treatment cycle)+vindesine 3 mg/m2 d1, d8 (3 weeks constitute one treatment cycle).
The research results of groups A and B were evaluated at week 12: for the two groups, the ORRs at week 12 are 62.5% and 83.3%, respectively, and complete response (CR) is observed in one case of 23 patients aged 16 or over.
| Number | Date | Country | Kind |
|---|---|---|---|
| 201910315417.X | Apr 2019 | CN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2020/085552 | 4/20/2020 | WO | 00 |
